MedTrace Logo

The Bladder Instillation Comparison Study

NCT02695771 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 101

Last updated 2023-04-21

Study results available
· View outcomes & findings →

Summary

To compare the efficacy of Mitomycin C vs. Gemcitabine vs. no adjuvant treatment as a single intraoperative instillation in preventing recurrence of bladder cancer.

Conditions

  • Urinary Bladder Neoplasms

Interventions

DRUG

Mitomycin C

Cancer chemotherapeutic agent

DRUG

Gemcitabine

Cancer chemotherapeutic agent

Sponsors & Collaborators

  • Spectrum Health Hospitals

    lead OTHER

Principal Investigators

  • Brian R Lane, MD · Spectrum Health Hospitals

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-04-19
Primary Completion
2021-10-22
Completion
2021-10-22

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02695771 on ClinicalTrials.gov